EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma.

• Wick, Wolfgang University of Heidelberg Medical Center, Heidelberg, Germany;
• Brandes, Alba Ariela Azienda USL Bellaria-Maggiore Hospital, Bologna, Italy;
• Gorlia, Thierry European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium;
• Bendszus, Martin Heidelberg University Hospital, Heidelberg, Germany;
• Sahm, Felix Heidelberg University Hospital, German Cancer Research Center (DKFZ), Heidelberg, Germany;
• Taal, Walter Erasmus MC, Rotterdam, Netherlands;
• Taphoorn, Martin J.B. Medical Center Haaglanden, The Hague, Netherlands;
• Domont, Julien Institut Gustave Roussy, Villejuif, France;
• Idbaih, Ahmed Universite Pierre et Marie Curie Paris VI, Paris, France;
• Campone, Mario Cancer Institute of the West (ICO), Centre René Gauducheau, Medical Oncology Department, Saint-Herblain, France;
• Clement, Paul M. UZ Leuven-Gasthuisberg, Leuven, Belgium;
• Stupp, Roger University of Lausanne Hospitals, Lausanne, Switzerland;
• Fabbro, Michel ICM Val d'Aurelle, Montpellier, France;
• Le Rhun, Emilie Centre Oscar Lambret, Lille, France;
• Dubois, François CHRU, Lille, France;
• Klein, Martin VU Amsterdam, Amsterdam, Netherlands;
• Platten, Michael Heidelberg University Hospital,German Cancer Research Center (DKFZ), Heidelberg, Germany;
• Weller, Michael University Hospital Zurich, Zurich, Switzerland;
• Golfinopoulos, Vassilis European Organization for Research and Treatment of Cancer, Brussels, Belgium;
• Van Den Bent, Martin J. Daniel den Hoed Cancer Center, Rotterdam, Netherlands;

Cancer Research

Oncology